Loading…
Loading…
If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.
Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript
The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.
Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange traded fund launched on December 31, 2014.
ALPS Medical Breakthroughs ETF targets late-stage clinical trial biotechs primed for outsized performance and M&A. SBIO's selective criteria focus on U.S.-listed firms with strong cash positions, Phase 2/3 assets, and near-term catalysts, creating a portfolio of high-volatility, high-alpha 'lottery tickets.' SBIO has delivered 111% returns over the past year, outperforming the S&P 500; its holdings have seen notable buyouts and clinical milestones.
Biotech stocks delivered their best single month since late 2023 in June, carrying the ALPS Medical Breakthroughs ETF (SBIO) to one of the top returns across the ALPS lineup. Key Takeaways: SBIO returned 18.7% in June, its best single month since December 2023.